SAFETY DATA SHEETS

This SDS packet was issued with item:

078904890

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078572713

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078904889 078905723

MATERIAL SAFETY DATA SHEET

Product Name: LEVOPHED (norepinephrine bitartrate) Injection, USP

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name And Address	Hospira Inc. 275 North Field Drive Lake Forest, Illinois USA 60045
Emergency Telephone	CHEMTREC: North America: 800-424-9300; International 1-703-527-3887; Australia (02) 8014 4880
Hospira, Inc., Non-Emergency	224-212-2000
Product Name	LEVOPHED (norepinephrine bitartrate) Injection, USP
Synonyms	Levarterenol bitartrate; (-)-α-(aminomethyl)-3,4-dihydroxybenzyl alcohol tartrate (1:1) (salt) monohydrate; (-)-Norepinephrine bitartrate salt monohydrate; L-Noradrenaline bitartrate monohydrate.

2. COMPOSITION/INFORMATION ON INGREDIENTS

Active Ingredient Name	L-Norepinephrine Bitartrate Monohydrate
Chemical Formula	$C_8H_{11}NO_3 \bullet C_4H_6O_6 \bullet H_2O$
Preparation	Non-hazardous ingredients include Water for Injection. Hazardous ingredients present at less than 1% include sodium chloride and sodium metabisulfite.

Component	Approximate Percent by Weight	CAS Number	RTECS Number
L-Norepinephrine Bitartrate Monohydrate	0.1	108341-18-0	NA

3. HAZARD INFORMATION

Carcinogen List

Substance	IARC	NTP	OSHA
L-Norepinephrine Bitartrate Monohydrate	Not Listed	Not Listed	Not Listed

Emergency Overview	LEVOPHED (norepinephrine bitartrate) Injection, USP is a solution containing norepinephrine bitartrate, a vasoconstrictor agent, and sodium metabisulfite, a preservative. In the workplace, this material should be considered possibly irritating to the skin, eyes and respiratory tract. The metabisulfite preservative may induce allergic reactions in people sensitive to sulfites. Possible target organs include the nervous system, cardiovascular system, respiratory system, and skin.
Occupational Exposure Potential	Information on the absorption of this product via inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.
Signs and Symptoms	None known from occupational exposure. This product contains sodium metabisulfite which may cause allergic-type reactions, including anaphylactic symptoms and/or life-threatening asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown, but occurs more frequently in asthmatics than in non-asthmatics. In clinical use, adverse effects may include hypertension, bradycardia, restlessness,

	palpitations, tremor, weakness, headache and elevated blood pressure. Overdosage can result in severe hypertension, bradycardia, increased peripheral resistance, decreased cardiac output and potentially fatal arrhythmias including ventricular tachycardia and fibrillation. Prolonged administration can result in depletion of plasma volume and electrolyte imbalance. Administration to pregnant women can cause fetal anoxia by provoking uterine contractions; therefore, the drug should not be used during pregnancy.
Medical Conditions Aggravated by Exposure	Pre-existing hypersensitivity to sulfites or related materials; concurrent therapy with monoamine oxidase inhibitors or related drugs. Pre-existing nervous system, cardiovascular system, respiratory system, or skin ailments.

4. FIRST AID MEASURES

Eye contact	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Skin contact	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Inhalation	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Ingestion	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability	None anticipated for this aqueous product.
Fire & Explosion Hazard	None anticipated for this aqueous product.
Extinguishing media	As with any fire, use extinguishing media appropriate for primary cause of fire.
Special Fire Fighting Procedures	No special provisions required beyond normal firefighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal	Isolate area around spill. Put on suitable protective clothing and equipment as specified by site spill procedures. Absorb the liquid with suitable material and clean affected area with soap and water. Dispose of spill materials according to the applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

Handling	No special handling required for hazard control under conditions of normal product use.
Storage	No special storage required for hazard control. For product protection, follow storage recommendations noted on the product case label, the primary container label, or the product insert.

Special Precautions No special precautions required for hazard control.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

	Exposure limits				
Component	**Type**	**mg/m3**	**ppm**	**µg/m3**	**Note**
L-Norepinephrine Bitartrate Monohydrate	Hospira EEL	N/A	N/A	0.5	
L-Norepinephrine Bitartrate Monohydrate	Hospira STEL	N/A	N/A	5	

Respiratory protection Respiratory protection is normally not needed during intended product use. However, if the generation of aerosols is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (N95 or equivalent) is recommended under conditions where airborne aerosol concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit tested and approved for respirator use as required.

Skin protection If skin contact with the product formulation is likely, the use of latex or nitrile gloves is recommended.

Eye protection Eye protection is normally not required during intended product use. However, if eye contact is likely to occur, the use of chemical safety goggles (as a minimum) is recommended.

Engineering Controls Engineering controls are normally not needed during the normal use of this product.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State Liquid
Color Clear, Colorless
Odor None
Odor Threshold: NA
pH: 3 - 4.5
Melting point/Freezing point: NA
Initial Boiling Point/Boiling Point Range: NA
Evaporation Rate: NA
Flammability (solid, gas): NA
Upper/Lower Flammability or Explosive Limits: NA
Vapor Pressure: NA
Vapor Density: NA
Specific Gravity: NA
Solubility: Norepinephrine is sparingly soluble in water, very slightly soluble in alcohol and ether, and readily soluble in acids.
Partition coefficient: n-octanol/water: NA
Auto-ignition temperature: NA

Decomposition temperature: NA

10. STABILITY AND REACTIVITY

Reactivity Not determined.

Chemical Stability Stable under standard use and storage conditions.

Hazardous Reactions Not determined

Conditions to avoid Not determined

Incompatibilities Not determined

Hazardous decomposition products Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of carbon oxides (COx) and nitrogen oxides (NOx).

Hazardous Polymerization Not anticipated to occur with this product.

11. TOXICOLOGICAL INFORMATION

Acute Toxicity
Not determined for the product formulation. Information for the ingredients is as follows:

Ingredient(s)	Percent	Test Type	Route of Administration	Value	Units	Species
l-Norepinephrine bitartrate	100	LD50	Intravenous	210	mcg/kg	Rat
l-Norepinephrine bitartrate	100	LD50	Intravenous	1.03	mg/kg	Mouse
l-Norepinephrine bitartrate	100	LD50	Intraperitoneal	26.8	mg/kg	Mouse
l-Norepinephrine	100	LD50	Oral	20	mg/kg	Rat
l-Norepinephrine	100	LD50	Intravenous	550 250 100	mcg/kg mcg/kg mcg/kg	Mouse Rabbit Rat
l-Norepinephrine	100	LD50	Intraperitoneal	6	mg/kg	Mouse
l-Norepinephrine	100	LD50	Subcutaneous	5	mg/kg	Mouse

Aspiration Hazard None anticipated from normal handling of this product.

Dermal Irritation/Corrosion None anticipated from normal handling of this product. However, inadvertent contact with this product may be irritating to mucous membranes.

Ocular Irritation/Corrosion None anticipated from normal handling of this product. However, inadvertent contact of this product with eyes may produce irritation.

Dermal or Respiratory Sensitization None anticipated from normal handling of this product. However, this product contains sodium metabisulfite and may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown, but sulfite sensitivity occurs more frequently in asthmatic than in non-asthmatic people.

Reproductive Effects No studies have been conducted in animals with norepinephrine bitartrate. However, administration to pregnant women can cause fetal anoxia by

provoking uterine contractions; therefore, the drug should not be used during pregnancy.

Mutagenicity Studies to evaluate the genotoxic potential of norepinephrine bitartrate have not been conducted.

Carcinogenicity Long-term studies in animals to evaluate the carcinogenic potential of norepinephrine bitartrate have not been conducted.

Target Organ Effects Based on clinical use, possible target organs include the nervous system, cardiovascular system, respiratory system, or skin.

12. ECOLOGICAL INFORMATION

Aquatic Toxicity Not determined for product

Persistence/Biodegradability Not determined for product

Bioaccumulation Not determined for product

Mobility in Soil Not determined for product

13. DISPOSAL CONSIDERATIONS

Waste Disposal All waste materials must be properly characterized. Further, disposal should be performed in accordance with the federal, state or local regulatory requirements.

Container Handling and Disposal Dispose of container and unused contents in accordance with federal, state and local regulations.

14. TRANSPORTATION INFORMATION

ADR/ADG/ DOT STATUS: Not regulated

IMDG STATUS: Not regulated

ICAO/IATA STATUS: Not regulated

Transport Comments: None

15. REGULATORY INFORMATION

USA Regulations

Substance	TSCA Status	CERCLA Status	SARA 302 Status	SARA 313 Status	PROP 65 Status
L-Norepinephrine Bitartrate Monohydrate	Not Listed	Not Listed	Not Listed	Not Listed	Not Listed

RCRA Status Not Listed
U.S. OSHA Classification Target Organ Toxin
Possible Irritant

GHS Classification	*In the EU, classification under GHS/CLP does not apply to certain substances and mixtures, such as medicinal products as defined in Directive 2001/83/EC, which are in the finished state, intended for the final user:
Hazard Class	Not Applicable
Hazard Category	Not Applicable
Signal Word	Not Applicable
Symbol	Not Applicable
Prevention	P260 - Do not breathe dust/fume/gas/mist/vapors/spray.
Hazard Statement	Not Applicable
Response:	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention. Wash hands after handling. Get medical attention if you feel unwell.

EU Classification*

*Medicinal products are exempt from the requirements of the EU Dangerous Preparations Directive. Information provided below is for the pure drug substance L-Norepinephrine Bitartrate Monohydrate

.

Classification(s):	Not Applicable
Symbol:	Not Applicable
Indication of Danger:	Not Applicable
Risk Phrases:	Not Applicable
Safety Phrases:	S23 - Do not breathe vapors. S24 - Avoid contact with skin. S25 - Avoid contact with eyes. S37/39 - Wear suitable gloves and eye/face protection.

16. OTHER INFORMATION:

Notes:

ACGIH TLV	American Conference of Governmental Industrial Hygienists – Threshold Limit Value
CAS	Chemical Abstracts Service Number
CERCLA	US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
DOT	US Department of Transportation Regulations
EEL	Employee Exposure Limit
IATA	International Air Transport Association
LD_{50}	Dosage producing 50% mortality
NA	Not applicable/Not available
NE	Not established
NIOSH	National Institute for Occupational Safety and Health
OSHA PEL	US Occupational Safety and Health Administration – Permissible Exposure Limit
Prop 65	California Proposition 65
RCRA	US EPA, Resource Conservation and Recovery Act
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
STEL	15-minute Short Term Exposure Limit
TSCA	Toxic Substance Control Act
TWA	8-hour Time Weighted Average

MSDS Coordinator: Hospira GEHS
Date Prepared: 10/13/2011
Obsolete Date: 01/07/2008

Disclaimer:
The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.

SAFETY DATA SHEET

Product Name: LEVOPHED (norepinephrine bitartrate) Injection, USP

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

Manufacturer Name And Address	Hospira, Inc. 275 North Field Drive Lake Forest, Illinois 60045 USA
Emergency Telephone	CHEMTREC: North America: 800-424-9300; International 1-703-527-3887; Australia - 61-290372994; UK - 44-870-8200418
Hospira, Inc., Non-Emergency	224 212-2000
Product Name	LEVOPHED (norepinephrine bitartrate) Injection, USP
Synonyms	(-)-α-(aminomethyl)-3,4-dihydroxybenzyl alcohol tartrate (1:1) (salt) monohydrate

2. HAZARD(S) IDENTIFICATION

Emergency Overview

LEVOPHED (norepinephrine bitartrate) Injection, USP is a solution containing norepinephrine bitartrate, a vasoconstrictor agent. Clinically, it is indicated for blood pressure control in certain acute hypotensive states. In the workplace, this material should be considered a potent drug, and possibly irritating to the skin, eyes and respiratory tract, and a possible sensitizer. Based on clinical use, possible target organs include the nervous system, cardiovascular system, and respiratory system.

U.S. OSHA GHS Classification

Physical Hazards	**Hazard Class**	**Hazard Category**
	Not Classified	Not Classified

Health Hazards	**Hazard Class**	**Hazard Category**
	Not Classified	Not Classified

Label Element(s)

Pictogram	NA
Signal Word	NA
Hazard Statement(s)	NA
Precautionary Statement(s)	
Prevention	Do not breathe vapor or spray Wash hands thoroughly after handling
Response	Get medical attention if you feel unwell
	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Active Ingredient Name (-)-Norepinephrine bitartrate salt monohydrate
Chemical Formula $C_8H_{11}NO_3 \bullet C_4H_6O_6 \bullet H_2O$

Component	Approximate Percent by Weight	CAS Number	RTECS Number
L-Norepinephrine Bitartrate Monohydrate	0.1	108341-18-0	NA

Non-hazardous ingredients include Water for Injection. Hazardous ingredients present at less than 1% include sodium chloride and sodium metabisulfite.

4. FIRST AID MEASURES

Eye Contact Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Skin Contact Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Inhalation Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Ingestion Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability None anticipated for this aqueous product.

Fire & Explosion Hazard None anticipated for this aqueous product.

Extinguishing Media As with any fire, use extinguishing media appropriate for primary cause of fire such as carbon dioxide, dry chemical extinguishing powder or foam.

Special Fire Fighting Procedures No special provisions required beyond normal firefighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal Isolate area around spill. Put on suitable protective clothing and equipment as specified by site spill control procedures. Absorb the liquid with suitable material and clean affected area with soap and water. Dispose of spill materials according to the applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

Handling No special handling required for hazard control under conditions of normal product use.

Storage No special storage required for hazard control. For product protection, follow storage recommendations noted on the product case label, the primary container label, or the product insert.

Special Precautions No special precautions required for hazard control.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

	Exposure Limits			
Component	**OSHA-PEL**	**ACGIH-TLV**	**AIHA WEEL**	**Hospira EEL**
Norepinephrine Bitartrate	8-hr TWA: Not Established	8-hr TWA: Not Established	8-hr TWA: Not Established	8 hr TWA: Not Established

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit
ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.
AIHA WEEL: Workplace Environmental Exposure Level
EEL: Employee Exposure Limit.
TWA: 8-hour Time Weighted Average.

Respiratory Protection

Respiratory protection is normally not needed during intended product use. However, if the generation of aerosols is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (N95 or equivalent) is recommended under conditions where airborne aerosol concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit tested and approved for respirator use as required.

Skin Protection

If skin contact with the product formulation is likely, the use of latex or nitrile gloves is recommended.

Eye Protection

Eye protection is normally not required during intended product use. However, if eye contact is likely to occur, the use of chemical safety goggles (as a minimum) is recommended.

Engineering Controls

Engineering controls are normally not needed during the normal use of this product.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State	Clear, colorless liquid.
Odor	NA
Odor Threshold	NA
pH	3 - 4.5
Melting point/Freezing Point	NA
Initial Boiling Point/Boiling Point Range	NA
Flash Point	NA
Evaporation Rate	NA
Flammability (solid, gas)	NA
Upper/Lower Flammability or Explosive Limits	NA
Vapor Pressure	NA
Vapor Density (Air =1)	NA
Relative Density	NA
Solubility	Norepinephrine is sparingly soluble in water, very slightly soluble in alcohol and ether, and readily soluble in acids.
Partition Coefficient: n-octanol/water	NA
Auto-ignition Temperature	NA
Decomposition Temperature	NA
Viscosity	NA

10. STABILITY AND REACTIVITY

Reactivity	Not determined.
Chemical Stability	Stable under standard use and storage conditions.
Hazardous Reactions	Not determined
Conditions to Avoid	Not determined
Incompatibilities	Not determined
Hazardous Decomposition Products	Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of carbon oxides (COx) and nitrogen oxides (NOx).
Hazardous Polymerization	Not anticipated to occur with this product.

11. TOXICOLOGICAL INFORMATION

Acute Toxicity - Not determined for the product formulation. Information for the active ingredient is as follows:

Ingredient(s)	Percent	Test Type	Route of Administration	Value	Units	Species
l-Norepinephrine bitartrate	100	LD50	Intravenous	210	mcg/kg	Rat
l-Norepinephrine bitartrate	100	LD50	Intravenous	1.03	mg/kg	Mouse
l-Norepinephrine bitartrate	100	LD50	Intraperitoneal	26.8	mg/kg	Mouse
l-Norepinephrine	100	LD50	Oral	20	mg/kg	Rat
l-Norepinephrine	100	LD50	Intravenous	550 250 100	mcg/kg mcg/kg mcg/kg	Mouse Rabbit Rat
l-Norepinephrine	100	LD50	Intraperitoneal	6	mg/kg	Mouse
l-Norepinephrine	100	LD50	Subcutaneous	5	mg/kg	Mouse

LD 50: Dosage that produces 50% mortality.

Occupational Exposure Potential	Some literature reports indicate that norepinephrine may be absorbed by inhalation. Information on the absorption of this product via skin contact is not available. Avoid liquid aerosol generation and skin contact.
Signs and Symptoms	None anticipated from normal handling of this product. In clinical use, adverse effects may include hypertension, bradycardia, restlessness, palpitations, tremor, weakness, headache and elevated blood pressure. Overdosage can result in severe hypertension, bradycardia, increased peripheral resistance, decreased cardiac output and potentially fatal arrhythmias including ventricular tachycardia and fibrillation. Prolonged administration can result in depletion of plasma volume and electrolyte imbalance. Administration to pregnant women can cause fetal anoxia by provoking uterine contractions; therefore, the drug should not be used during pregnancy.
Aspiration Hazard	None anticipated from normal handling of this product.
Dermal Irritation/ Corrosion	None anticipated from normal handling of this product. However, inadvertent contact with this product may be irritating to mucous membranes.
Ocular Irritation/ Corrosion	None anticipated from normal handling of this product. However, inadvertent contact of this product with eyes may produce irritation.
Dermal or Respiratory Sensitization	None anticipated from normal handling of this product. However, this product contains sodium metabisulfite and may cause allergic-type reactions, in persons sensitive to sulfites.

11. TOXICOLOGICAL INFORMATION: continued

Reproductive Effects	None anticipated from normal handling of this product. Animal reproduction studies have not been conducted with norepinephrine bitartrate. However, administration to pregnant women can cause fetal anoxia by provoking uterine contractions; therefore, the drug should not be used during pregnancy.
Mutagenicity	The genotoxic potential of norepinephrine bitartrate has not been evaluated.
Carcinogenicity	Long-term studies in animals to evaluate the carcinogenic potential of norepinephrine bitartrate have not been conducted.
Carcinogen Lists	**IARC:** Not listed **NTP:** Not listed **OSHA:** Not listed
Specific Target Organ Toxicity – Single Exposure	NA
Specific Target Organ Toxicity – Repeat Exposure	Based on clinical use, possible target organs include the nervous system, cardio-vascular system, and respiratory system.

12. ECOLOGICAL INFORMATION

Aquatic Toxicity	Not determined for product.
Persistence/Biodegradability	Not determined for product.
Bioaccumulation	Not determined for product.
Mobility in Soil	Not determined for product.

Notes:

13. DISPOSAL CONSIDERATIONS

Waste Disposal	All waste materials must be properly characterized. Further, disposal should be performed in accordance with the federal, state or local regulatory requirements.
Container Handling and Disposal	Dispose of container and unused contents in accordance with federal, state and local regulations.

14. TRANSPORTATION INFORMATION

ADR/ADG/ DOT STATUS	Not regulated
Proper Shipping Name	NA
Hazard Class	NA
UN Number	NA
Packing Group	NA
Reportable Quantity	NA
ICAO/IATA STATUS	Not regulated
Proper Shipping Name	NA
Hazard Class	NA
UN Number	NA
Packing Group	NA
Reportable Quantity	NA
IMDG STATUS	Not regulated
Proper Shipping Name	NA
Hazard Class	NA
UN Number	NA
Packing Group	NA
Reportable Quantity	NA

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

US TSCA Status	Exempt
US CERCLA Status	Not listed
US SARA 302 Status	Not listed
US SARA 313 Status	Not listed
US RCRA Status	Not listed
US PROP 65 (Calif.)	Not listed

Notes: TSCA, Toxic Substance Control Act; CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act; SARA, Superfund Amendments and Reauthorization Act; RCRA, US EPA, Resource Conservation and Recovery Act; Prop 65, California Proposition 65

GHS/CLP Classification*

*In the EU, classification under GHS/CLP does not apply to certain substances and mixtures, such as medicinal products as defined in Directive 2001/83/EC, which are in the finished state, intended for the final user.

Hazard Class	Hazard Category	Pictogram	Signal Word	Hazard Statement
NA	NA	NA	NA	NA

Prevention

Do not breathe vapor or spray
Wash hands thoroughly after handling

Response

Get medical attention if you feel unwell

IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention.

EU Classification*

*Medicinal products are exempt from the requirements of the EU Dangerous Preparations Directive.

Classification(s)	NA
Symbol	NA
Indication of Danger	NA
Risk Phrases	NA
Safety Phrases	S23: Do not breathe vapor/spray S24: Avoid contact with the skin S25: Avoid contact with eyes S37/39 Wear suitable gloves and eye/face protection.

16. OTHER INFORMATION

Notes:

ACGIH TLV	American Conference of Governmental Industrial Hygienists – Threshold Limit Value
CAS	Chemical Abstracts Service Number
CERCLA	US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
DOT	US Department of Transportation Regulations
EEL	Employee Exposure Limit
IATA	International Air Transport Association
LD_{50}	Dosage producing 50% mortality
NA	Not applicable/Not available
NE	Not established
NIOSH	National Institute for Occupational Safety and Health
OSHA PEL	US Occupational Safety and Health Administration – Permissible Exposure Limit
Prop 65	California Proposition 65
RCRA	US EPA, Resource Conservation and Recovery Act
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
STEL	15-minute Short Term Exposure Limit
STOT - SE	Specific Target Organ Toxicity – Single Exposure
STOT - RE	Specific Target Organ Toxicity – Repeated Exposure
TSCA	Toxic Substance Control Act
TWA	8-hour Time Weighted Average

MSDS Coordinator: Hospira GEHS
Date Prepared: October 18, 2012
Date Revised: June 02, 2014

Disclaimer:
The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.